SAR425899: Clinical Trials

4 completed. 4 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 4

Follow SAR425899: new trials by email Literature Review of SAR425899 trials Research Report on SAR425899

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects SAR425899, Placebo - Type 2 Diabetes Mellitus	Phase 1	Completed	Sanofi	24	2018-04-18	2022-04-25
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period SAR425899 - Type 2 Diabetes Mellitus	Phase 1	Completed	Sanofi	60	2018-01-19	2022-04-25
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer) - Type 2 Diabetes Mellitus	Phase 1	Completed	Sanofi	13	2017-12-20	2022-04-25
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients SAR425899, placebo, metformin - Type 2 Diabetes Mellitus	Phase 1	Completed	Sanofi	76	2015-03-01	2018-06-15

Conditions studied

Diabetes Mellitus, Type 2 (4)

Sponsors

Sanofi (4)

Countries

United States (2)  ·  Germany (1)  ·  Sweden (1)

Results publications

PMID 30091218, PMID 31808298, PMID 34503957

NIH funding

2014 (1), 2017 (1)